ResMed downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst David Low downgraded ResMed to Underweight and lowered his price target for the shares to A$13.40 from A$15.50 following the company’s fiscal Q2 results. Goldman Sachs this morning also downgraded ResMed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.